These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38753770)

  • 21. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-primed germinal centres with enduring affinity maturation and clonal migration.
    Lee JH; Sutton HJ; Cottrell CA; Phung I; Ozorowski G; Sewall LM; Nedellec R; Nakao C; Silva M; Richey ST; Torres JL; Lee WH; Georgeson E; Kubitz M; Hodges S; Mullen TM; Adachi Y; Cirelli KM; Kaur A; Allers C; Fahlberg M; Grasperge BF; Dufour JP; Schiro F; Aye PP; Kalyuzhniy O; Liguori A; Carnathan DG; Silvestri G; Shen X; Montefiori DC; Veazey RS; Ward AB; Hangartner L; Burton DR; Irvine DJ; Schief WR; Crotty S
    Nature; 2022 Sep; 609(7929):998-1004. PubMed ID: 36131022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination induces broadly neutralizing antibody precursors to HIV gp41.
    Schiffner T; Phung I; Ray R; Irimia A; Tian M; Swanson O; Lee JH; Lee CD; Marina-Zárate E; Cho SY; Huang J; Ozorowski G; Skog PD; Serra AM; Rantalainen K; Allen JD; Baboo S; Rodriguez OL; Himansu S; Zhou J; Hurtado J; Flynn CT; McKenney K; Havenar-Daughton C; Saha S; Shields K; Schultze S; Smith ML; Liang CH; Toy L; Pecetta S; Lin YC; Willis JR; Sesterhenn F; Kulp DW; Hu X; Cottrell CA; Zhou X; Ruiz J; Wang X; Nair U; Kirsch KH; Cheng HL; Davis J; Kalyuzhniy O; Liguori A; Diedrich JK; Ngo JT; Lewis V; Phelps N; Tingle RD; Spencer S; Georgeson E; Adachi Y; Kubitz M; Eskandarzadeh S; Elsliger MA; Amara RR; Landais E; Briney B; Burton DR; Carnathan DG; Silvestri G; Watson CT; Yates JR; Paulson JC; Crispin M; Grigoryan G; Ward AB; Sok D; Alt FW; Wilson IA; Batista FD; Crotty S; Schief WR
    Nat Immunol; 2024 Jun; 25(6):1073-1082. PubMed ID: 38816615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
    McGuire AT
    Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
    Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
    Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
    Williams WB; Wiehe K; Saunders KO; Haynes BF
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
    Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
    J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.
    Dubrovskaya V; Tran K; Ozorowski G; Guenaga J; Wilson R; Bale S; Cottrell CA; Turner HL; Seabright G; O'Dell S; Torres JL; Yang L; Feng Y; Leaman DP; Vázquez Bernat N; Liban T; Louder M; McKee K; Bailer RT; Movsesyan A; Doria-Rose NA; Pancera M; Karlsson Hedestam GB; Zwick MB; Crispin M; Mascola JR; Ward AB; Wyatt RT
    Immunity; 2019 Nov; 51(5):915-929.e7. PubMed ID: 31732167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
    Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
    PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection.
    Chan KW; Pan R; Costa M; Gorny MK; Wang S; Lu S; Kong XP
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29997214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates.
    Francica JR; Laga R; Lynn GM; Mužíková G; Androvič L; Aussedat B; Walkowicz WE; Padhan K; Ramirez-Valdez RA; Parks R; Schmidt SD; Flynn BJ; Tsybovsky Y; Stewart-Jones GBE; Saunders KO; Baharom F; Petrovas C; Haynes BF; Seder RA
    PLoS Biol; 2019 Jun; 17(6):e3000328. PubMed ID: 31206510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein.
    van Haaren MM; McCoy LE; Torres JL; Lee W; Cottrell CA; Copps JL; van der Woude P; Yasmeen A; de Taeye SW; Torrents de la Peña A; Moore JP; Burton DR; Klasse PJ; Ward AB; Sanders RW; van Gils MJ
    J Virol; 2021 Aug; 95(17):e0009421. PubMed ID: 34076487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells.
    Huang D; Tran JT; Olson A; Vollbrecht T; Tenuta M; Guryleva MV; Fuller RP; Schiffner T; Abadejos JR; Couvrette L; Blane TR; Saye K; Li W; Landais E; Gonzalez-Martin A; Schief W; Murrell B; Burton DR; Nemazee D; Voss JE
    Nat Commun; 2020 Nov; 11(1):5850. PubMed ID: 33203876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.
    Lin YR; Parks KR; Weidle C; Naidu AS; Khechaduri A; Riker AO; Takushi B; Chun JH; Borst AJ; Veesler D; Stuart A; Agrawal P; Gray M; Pancera M; Huang PS; Stamatatos L
    Immunity; 2020 Oct; 53(4):840-851.e6. PubMed ID: 33053332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer.
    Lee JH; Nakao C; Appel M; Le A; Landais E; Kalyuzhniy O; Hu X; Liguori A; Mullen TM; Groschel B; Abbott RK; Sok D; Schief WR; Crotty S
    Cell Rep; 2022 Mar; 38(10):110485. PubMed ID: 35263576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.